GlassScriptPhysician profile
Majed A Koleilat
NPI 1922175694
$121,827.89
in general payments reported to CMS, 2019-2025
45 companies · $22K in 2025
The $22K reported for 2025 was more than what 92% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $8,447 · 2021: $12K · 2022: $6,074 · 2023: $11K · 2024: $40K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Food and Beverage: $8,001 · Travel and Lodging: $2,280 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,200.00 |
| Food and Beverage | $8,000.95 |
| Travel and Lodging | $2,280.39 |
| Education | $310.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $99,776.02 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Genentech USA, INC. | $5,891.29 | 2019-2025 | Xolair |
| Biocryst Pharmaceuticals, INC. | $3,312.58 | 2019-2020 | |
| Glaxosmithkline, LLC. | $1,639.84 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,632.29 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,580.00 | 2019-2025 | Dupixent |
| Csl Behring | $1,457.69 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Biocryst US Sales Co., LLC | $1,172.71 | 2021-2025 | Orladeyo |
| Amgen INC. | $449.81 | 2021-2025 | Tezspire |
| Grifols USA, LLC | $409.27 | 2019-2024 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Pharming Healthcare, INC. | $364.70 | 2019-2025 | Ruconest |
| Galderma Laboratories, L.P. | $352.17 | 2025 | Nemluvio |
| Takeda Pharmaceuticals U.S.A., INC. | $344.81 | 2020-2025 | Takhzyro |
| Novartis Pharmaceuticals Corporation | $296.30 | 2019-2025 | |
| Pfizer INC. | $265.86 | 2019-2023 |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majed Koleilat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.